We designed a randomized trial to assess whether the early withdrawal of cyclosporine (CsA) followed by the initiation of everolimus (Evr) monotherapy in de novo liver transplantation (LT) patients would result in superior renal function compared to a CsA-based im- munosuppression protocol. All patients were treated with CsA for the first 10 days and then randomized to receive Evr in combination with CsA up to day 30, then either continued on Evr monotherapy (Evr group) or maintained on CsA with/without mycophenolate mofetil (CsA group) in case of chronic kidney disease (CKD). Seventy-eight patients were randomized (Evr n = 52; CsA n = 26). The 1-year freedom from effi- cacy failure in Evr group was 75% versus 69.2% in CsA group, p = 0.36. There was no statistically significant difference in patient survival between the two groups. Mean modification of diet in renal disease (MDRD) was significantly better in the Evr group at 12 months (87.7 ± 26.1 vs. 59.9 ± 12.6 mL/min; p < 0.001). The incidence of CKD stage ≥3 (estimated glomerular fil- tration rate <60 mL/min) was higher in the CsA group at 1 year (52.2% vs. 15.4%, p = 0.005). The results in- dicate that early withdrawal of CsA followed by Evr monotherapy in de novo LT patients is associated with an improvement in renal function, with a similar inci- dence of rejection and major complications.

Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function / Masetti, Michele; Montalti, R.; Rompianesi, Gianluca; Codeluppi, M.; Gerring, R.; Romano, Antonio; Begliomini, Bruno; DI BENEDETTO, Fabrizio; Gerunda, Giorgio Enrico. - In: AMERICAN JOURNAL OF TRANSPLANTATION. - ISSN 1600-6135. - STAMPA. - 10:(2010), pp. 2252-2262. [10.1111/j.1600-6143.2010.03128.x]

Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function

MASETTI, Michele;Rompianesi, Gianluca;ROMANO, Antonio;BEGLIOMINI, Bruno;DI BENEDETTO, Fabrizio;GERUNDA, Giorgio Enrico
2010

Abstract

We designed a randomized trial to assess whether the early withdrawal of cyclosporine (CsA) followed by the initiation of everolimus (Evr) monotherapy in de novo liver transplantation (LT) patients would result in superior renal function compared to a CsA-based im- munosuppression protocol. All patients were treated with CsA for the first 10 days and then randomized to receive Evr in combination with CsA up to day 30, then either continued on Evr monotherapy (Evr group) or maintained on CsA with/without mycophenolate mofetil (CsA group) in case of chronic kidney disease (CKD). Seventy-eight patients were randomized (Evr n = 52; CsA n = 26). The 1-year freedom from effi- cacy failure in Evr group was 75% versus 69.2% in CsA group, p = 0.36. There was no statistically significant difference in patient survival between the two groups. Mean modification of diet in renal disease (MDRD) was significantly better in the Evr group at 12 months (87.7 ± 26.1 vs. 59.9 ± 12.6 mL/min; p < 0.001). The incidence of CKD stage ≥3 (estimated glomerular fil- tration rate <60 mL/min) was higher in the CsA group at 1 year (52.2% vs. 15.4%, p = 0.005). The results in- dicate that early withdrawal of CsA followed by Evr monotherapy in de novo LT patients is associated with an improvement in renal function, with a similar inci- dence of rejection and major complications.
10
2252
2262
Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function / Masetti, Michele; Montalti, R.; Rompianesi, Gianluca; Codeluppi, M.; Gerring, R.; Romano, Antonio; Begliomini, Bruno; DI BENEDETTO, Fabrizio; Gerunda, Giorgio Enrico. - In: AMERICAN JOURNAL OF TRANSPLANTATION. - ISSN 1600-6135. - STAMPA. - 10:(2010), pp. 2252-2262. [10.1111/j.1600-6143.2010.03128.x]
Masetti, Michele; Montalti, R.; Rompianesi, Gianluca; Codeluppi, M.; Gerring, R.; Romano, Antonio; Begliomini, Bruno; DI BENEDETTO, Fabrizio; Gerunda, Giorgio Enrico
File in questo prodotto:
File Dimensione Formato  
Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 357.95 kB
Formato Adobe PDF
357.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/860258
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 112
  • ???jsp.display-item.citation.isi??? 108
social impact